Non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver condition worldwide, affecting roughly 25% of adults — and its prevalence is climbing in lockstep with obesity and type 2 diabetes. For most, it begins silently: an accumulation of fat droplets inside hepatocytes that, over years, can progress through inflammation (non-alcoholic steatohepatitis, or NASH) toward fibrosis, cirrhosis, and hepatocellular carcinoma. Current management centres on lifestyle modification and metabolic control — weight loss, exercise, glucose regulation — but no pharmacotherapy is approved specifically for NAFLD. It is precisely this therapeutic vacuum that mesenchymal stem cell (MSC) research hopes to address.

Where conventional care falls short. Lifestyle interventions are effective when sustained, but adherence is poor and the window for reversal narrows once significant fibrosis develops. The disease is driven by a complex interplay of hepatic lipid accumulation, oxidative stress, mitochondrial dysfunction, and chronic low-grade inflammation — a web that no single lifestyle change fully untangles. Patients with NASH and F2–F3 fibrosis face an elevated risk of progression to cirrhosis, yet have no approved drug to slow that trajectory.

The deeper problem is metabolic. NAFLD is not simply a liver disease — it is the hepatic manifestation of systemic metabolic dysfunction. Insulin resistance drives excess free fatty acid flux to the liver; adipokine imbalance and gut-derived endotoxins fuel hepatic inflammation; and activated Kupffer cells and recruited macrophages sustain a pro-fibrotic milieu. A therapy that could simultaneously reduce steatosis, dampen inflammation, and interrupt fibrogenesis would address the disease at its roots.

MSC therapy targets multiple pathways simultaneously. Rather than blocking a single receptor or enzyme, MSCs sense the injured metabolic environment and respond with a coordinated paracrine program — anti-inflammatory cytokines, anti-fibrotic factors, and hepatoprotective growth factors — that several preclinical models suggest can reduce liver fat, lower inflammatory markers, and slow fibrosis progression.[1][2]

What goes wrong in the fatty liver

NAFLD begins with hepatic steatosis — the accumulation of triglyceride droplets within hepatocytes — driven by an imbalance between fatty acid uptake, de novo lipogenesis, fatty acid oxidation, and triglyceride export. When the liver's capacity to handle this lipid surplus is exceeded, lipotoxic intermediates accumulate, triggering endoplasmic reticulum stress, mitochondrial injury, and the release of damage-associated molecular patterns that activate innate immune pathways.[3][4]

The transition from simple steatosis to NASH is the critical inflection point. Hepatocyte injury and death release signals that activate Kupffer cells — the liver's resident macrophages — shifting them toward a pro-inflammatory M1 phenotype. These activated macrophages secrete TNF-α, IL-1β, and TGF-β, which in turn activate hepatic stellate cells, the primary collagen-producing cells in the liver. The result is a self-perpetuating cycle: inflammation → stellate cell activation → fibrosis → further hepatocyte injury → more inflammation. Breaking this cycle is the central therapeutic challenge in NAFLD.[5][6]

Why mesenchymal stem cells are the leading candidate

MSCs are an unusually good biological fit for the NAFLD problem because they address several of its core drivers at once. Their therapeutic potential rests on three main pillars: immunomodulation (shifting macrophage polarization from M1 to M2, expanding regulatory T cells, suppressing pro-inflammatory cytokine production), anti-fibrotic activity (reducing hepatic stellate cell activation and promoting collagen degradation via matrix metalloproteinases), and metabolic support (improving insulin sensitivity, reducing hepatic lipid accumulation, and protecting hepatocytes from lipotoxic injury through paracrine factors including HGF, IGF-1, and FGF-21).[7][8][9]

Importantly, MSCs are not expected to replace lost hepatocytes or regrow liver mass. Their value lies in modulating the disease environment — calming the inflammatory response that drives the steatosis-to-NASH-to-fibrosis cascade, and tipping the balance away from fibrogenesis. In animal models of diet-induced NAFLD and NASH, MSC infusion has consistently reduced hepatic steatosis, lowered serum ALT and AST, decreased inflammatory cytokine levels, and attenuated collagen deposition. Whether these effects translate durably to human disease is the critical open question.[10][11]

What the human trials show so far

The clinical evidence for MSCs in NAFLD is early and limited, but growing. Most published studies are small phase I/II trials, typically enrolling patients with biopsy-confirmed NASH and F1–F3 fibrosis. Across these studies, intravenous or hepatic-artery infusion of umbilical-cord-derived or bone-marrow-derived MSCs has been reported as safe and well tolerated, with no serious adverse events attributed to the cell product.[12]

Efficacy signals are preliminary but directionally consistent. Several trials have reported statistically significant reductions in liver fat fraction measured by MRI-PDFF, decreases in serum ALT and AST, and improvements in homeostasis model assessment of insulin resistance (HOMA-IR) at 24–48 weeks post-infusion. A small number of studies have also described histological improvements — reduced NAFLD Activity Score (NAS) and, in some patients, at least one stage of fibrosis regression — on follow-up biopsy. These are encouraging signals, but they come from underpowered studies with short follow-up and variable cell preparation protocols.

The honest headline

As of today, no MSC therapy is approved for NAFLD or NASH anywhere in the world. The credible work is in early-phase clinical trials that have established safety and reported preliminary metabolic and histological signals. No large, randomised, placebo-controlled phase III trial has yet demonstrated durable histological improvement or — critically — a reduction in progression to cirrhosis, decompensation, or liver-related mortality. Any clinic presenting stem cell therapy as a reliable NAFLD cure is going well beyond the data.

How liver outcomes are measured in NAFLD trials

Understanding whether a therapy works in NAFLD requires objective, standardised assessments. The gold standard is liver biopsy with histological scoring — the NAFLD Activity Score (NAS) grades steatosis, lobular inflammation, and hepatocyte ballooning on a 0–8 scale, while fibrosis is staged separately from F0 (none) to F4 (cirrhosis). In early-phase trials, less invasive measures are often used: MRI-PDFF (proton density fat fraction) quantifies liver fat with high precision, transient elastography (FibroScan) estimates liver stiffness as a proxy for fibrosis, and serum biomarkers — ALT, AST, CK-18 fragments, FIB-4 index — track hepatocellular injury and fibrosis risk. The regulatory bar, however, remains histological: a therapy that does not demonstrate fibrosis improvement on biopsy in a well-controlled trial cannot claim to modify disease progression.

What the evidence supports — and what it does not

A fair reading of today's evidence yields a nuanced picture. MSC therapy for NAFLD has a plausible biological rationale grounded in anti-inflammatory, anti-fibrotic, and metabolic mechanisms demonstrated in preclinical models. Early clinical safety data are reassuring. Preliminary efficacy signals — reduced liver fat on MRI, lower transaminases, improved insulin sensitivity — are directionally promising but come from small, heterogeneous studies. What is absent is definitive proof of histological benefit in a large, randomised, controlled trial, and — most importantly — evidence that MSC therapy prevents progression to cirrhosis or reduces liver-related mortality. Until that exists, the responsible characterisation is investigational.

NAFLD is the kind of widespread, slowly progressive condition where the gap between "promising early signal" and "proven treatment" is easily exploited. The most ethical thing we can offer patients is clarity about what we know, what we do not, and what the research is genuinely trying to achieve.

— VELAR Clinical Team

How to evaluate any NAFLD stem cell offer responsibly

If you are considering stem cell therapy for fatty liver disease, the same due diligence that protects against any over-promised treatment applies. Ask whether the approach is part of a registered clinical trial with ethical oversight. Ask what specific cell type is used, at what dose, and via what route. Ask how outcomes are measured — ideally with MRI-PDFF and/or biopsy, not just "how the patient feels." Be deeply sceptical of guaranteed results, success-rate claims without a published source, or any framing that presents experimental cell therapy as a routine substitute for metabolic management. A trustworthy provider will describe MSC therapy for NAFLD as an area of active investigation, not as an established treatment — and will never let hope outrun the data.

The VELAR perspective

At VELAR Center, our regenerative protocols are grounded in conditions where the clinical evidence is more mature, and we follow hepatology cell-therapy research closely without overstating its current status. NAFLD represents one of the largest unmet needs in hepatology, and the biological rationale for MSC intervention is compelling — but the gap between preclinical promise and proven clinical benefit remains wide. We believe the only honest way to discuss it is plainly: the science is real, the early signals are intriguing, the definitive evidence is not yet in, and it is investigational — never a replacement for metabolic management, hepatology follow-up, or, in advanced disease, transplant evaluation. As the evidence matures, we will let that evidence — not enthusiasm — shape anything we say about it. If you want an honest, evidence-based conversation about what regenerative medicine can and cannot offer for metabolic liver disease today, that is precisely where a responsible consultation begins.

References

  1. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Reviews Immunology. 2008;8(9):726-736. doi:10.1038/nri2395 ↩
  2. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 ↩
  3. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine. 2018;24(7):908-922. doi:10.1038/s41591-018-0104-9 ↩
  4. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537-2564. doi:10.1016/j.cell.2021.04.015 ↩
  5. Tacke F. Targeting hepatic macrophages to treat liver diseases. Journal of Hepatology. 2017;66(6):1300-1312. doi:10.1016/j.jhep.2017.02.026 ↩
  6. Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nature Reviews Gastroenterology & Hepatology. 2017;14(7):397-411. doi:10.1038/nrgastro.2017.38 ↩
  7. Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Research & Therapy. 2016;7(1):125. doi:10.1186/s13287-016-0363-7 ↩
  8. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. doi:10.1016/j.stem.2018.05.004 ↩
  9. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regenerative Medicine. 2019;4:22. doi:10.1038/s41536-019-0083-6 ↩
  10. Watanabe T, Tsuchiya A, Takeuchi S, et al. A systematic review of mesenchymal stem cell therapy for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Stem Cell Research & Therapy. 2022;13(1):15. doi:10.1186/s13287-021-02688-2 ↩
  11. Kuo TK, Hung SP, Chuang CH, et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology. 2008;134(7):2111-2121.e3. doi:10.1053/j.gastro.2008.03.015 ↩
  12. Sakai Y, Takamura M, Seki A, et al. Phase I clinical study of liver regenerative therapy for cirrhosis by intrahepatic arterial infusion of autologous adipose tissue-derived stromal cells. Regenerative Therapy. 2017;6:52-60. doi:10.1016/j.reth.2017.01.002 ↩
  13. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  14. Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Translational Medicine. 2017;6(6):1445-1451. doi:10.1002/sctm.17-0051 ↩
  15. Naji A, Eitoku M, Favier B, Deschaseaux F, Rouas-Freiss N, Suganuma N. Biological functions of mesenchymal stem cells. Cellular and Molecular Life Sciences. 2019;76(17):3323-3348. doi:10.1007/s00018-019-03125-1 ↩